Evidence map›Paper›PMID 41635407›Full record

ArticleFrontiers in oncology2025

Koumine exerts its anti-colorectal cancer effects by disrupting the interaction between HSP90 and CDC37, thereby downregulating downstream signaling pathways.

HaiLing Lin, YuXuan Bao, XiTong Cheng, ShuMing Zhang, DanYang Zhou, WanCai Que

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

HaiLing Lin *Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
YuXuan Bao *Phase I Clinical Trial Unit, Fujian Medical University Union Hospital, Fuzhou, China.
XiTong ChengPhase I Clinical Trial Unit, Fujian Medical University Union Hospital, Fuzhou, China.
ShuMing ZhangPhase I Clinical Trial Unit, Fujian Medical University Union Hospital, Fuzhou, China.
DanYang ZhouDepartment of Respiratory, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
WanCai QueDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Koumine, a principal bioactive alkaloid derived from the traditional Chinese herb Methods: We employed an integrated strategy combining network pharmacology prediction with experimental validation. Bioinformatics analysis was conducted to identify potential targets. In vitro functional assays were performed to evaluate effects on cell proliferation, clonogenicity, apoptosis, migration, and invasion. Target engagement was confirmed by cellular thermal shift assay (CETSA), and the molecular mechanism was investigated through Western blot and co-immunoprecipitation analyses. Results: Network pharmacology identified heat shock protein 90 (HSP90) as a key potential target, a finding supported by molecular docking simulations. Koumine significantly inhibited the malignant phenotypes of CRC cells. CETSA confirmed direct binding of koumine to HSP90. Mechanistically, koumine disrupted the functional interaction between HSP90 and its co-chaperone CDC37, leading to the downregulation and inactivation of critical downstream client proteins, including cyclin-dependent kinases CDK4 and CDK6. Discussion: These findings elucidate that koumine exerts potent anti-CRC effects primarily by targeting the HSP90-CDC37 chaperone complex and inhibiting the CDK4/6-Rb signaling axis. This study provides a robust mechanistic foundation and compelling preclinical evidence for the further development of koumine as a promising therapeutic agent for colorectal cancer.

Indexed as

CDC37colorectal cancerHSP90kouminenetwork pharmacology

Identifiers

PMID41635407
PMCPMC12861894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.